Analysts have been eager to weigh in on the Healthcare sector with new ratings on Moderna (MRNA – Research Report), Genmab (GMAB – Research Report) and Adaptimmune Therapeutics (ADAP – Research Report). Moderna (MRNA) Brookline Capital Markets analyst Leah R. Cann maintained a Buy rating on Moderna today and set a price target of $506.00. The company's shares closed last Monday at $179.50. According to TipRanks.
https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-moderna-mrna-genmab-gmab-and-adaptimmune-therapeutics-adap?utm_source=advfn.com&utm_medium=referral